title: Shifting the Evolving CAR T Cell Platform into Higher Gear.
abstract: In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion. The results have important implications for the development of effective CAR T cell therapies in cancer patients.
authors.affiliation: UCSF Diabetes Center and Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA.
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Holohan
authors.affiliation: UCSF Diabetes Center and Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA.
authors.forename: James C
authors.initials: JC
authors.lastname: Lee
authors.affiliation: UCSF Diabetes Center and Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA. Electronic address: jeff.bluestone@ucsf.edu.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Bluestone
mesh_terms: D018106:CD28 Antigens / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000276:immunology*; D006801:Humans; D011946:Receptors, Antigen / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000276:immunology*
chemical_list: D018106:CD28 Antigens; D011946:Receptors, Antigen; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9